Encephalomalacia Market Research Report- Global Forecast till 2023

Encephalomalacia Market Research Report: By Types (Leukoencephalomalacia, Polioencephalomalacia), Diagnosis (Brain Scans, Computerized Tomography Scan) Treatment (Medical Treatment, Surgery), End User (Hospitals & Clinics) - Global Forecast Till 2023 

ID: MRFR/MED/3627-HCR | | Region: Global | 80 pages

Market Scenario


Softening or loss of brain tissue is termed as encephalomalacia and is a severe type of brain damage. Encephalomalacia disorder can also be classified into the three categories depending on their colors and the stages of damage i.e. red softening yellow softening, and white softening. The major causes of encephalomalacia are inflammation or hemorrhages that are a consequence of being afflicted by cerebral infarction, cerebral ischemia, infection, craniocerebral trauma, or another injury. Moreover, stroke is the most commonly known cause of encephalomalacia and stroke can be caused by either a head injury or a brain hemorrhage or both of them cause internal bleeding in brain. Furthermore, strokes occur due to reduced or interrupted blood supply to the brain, which is caused by blocked arteries or a burst blood vessel. Moreover, people with diabetes, blood sugar levels that become too high (hyperglycemia) or too low (hypoglycemia) which increases chances of strokes. People who have been rescued from drowning or those who have been resuscitated after a heart attack may not awaken due to lack of oxygen to the brain. Furthermore infections such as encephalitis and meningitis cause swelling or inflammation of the brain, spinal cord or the tissues that surround the brain in severe cases of these infections can result in brain disorder.


Increasing prevalence of neurological disorders, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the market. Moreover, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases will fuel the market growth during the forecast period


Furthermore, globalization in healthcare has increased the market growth. Established market players in the developed countries leads the globalization by pushing new products and services into the developing countries and emerging economies. 


According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high-income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden, which is expected to increase further over the coming years.


However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.


The global encephalomalacia market is expected to grow at a CAGR of ~6.1% during the forecast period 2017-2023.


 


Intended Audience



  • Pharmaceutical and Biotechnological Companies

  • Research and Development (R&D) Companies

  • Ambulatory Care Centers

  • Academic Institutes and Universities

  • Market Research and Consulting Service Providers

  • Potential Investors


 


Figure: Global Encephalomalacia Market, By Region Market Share, 2016 (%)
Encephalomalacia Market


Sources: Annual reports, Press release, White paper, Company presentation


Segmentations


The global encephalomalacia market is segmented on the basis of types, diagnosis, treatment, and end user.


On the basis of the type, it is segmented into leukoencephalomalacia (encephalomalacia affecting the white matter), and polioencephalomalacia (encephalomalacia affecting the gray matter).  


On the basis of the diagnosis, it is segmented into blood test, brain scans, and others. A brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG).


On the basis of the treatment, it is segmented into medical treatment, surgery, and others.


On the basis of the end user, it is segmented into hospitals & clinics, research laboratories, and others.


Regional Analysis


The Americas dominate the global encephalomalacia market owing to well-developed technology, increasing prevalence of brain disorder, high health care spending, and increasing government support for research & development in the healthcare sector. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.


Europe holds the second position in the global encephalomalacia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.     


The Asia Pacific is the fastest growing encephalomalacia market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.   


On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.


Key Players


Some of key the players in the market are Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Carestream Health (U.S.), Nihon Kohden Corporation (Japan), Electrical Geodesics Inc. (U.S.), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy), and others.


Research Methodology


Global Encephalomalacia Market


Sources: Annual reports, Press release, White paper, and Company presentation






Frequently Asked Questions (FAQ) :


Softening of brain tissue leasing to severe brain damage is known as encephalomalacia.

The players in the encephalomalacia market are GE Healthcare (U.S.), Siemens Healthcare(U.S.), Fujifilm Holdings (Japan), Shimadzu Corporation (Japan), Philips Healthcare (U.S.), Carestream Health (U.S.), Nihon Kohden Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy), Electrical Geodesics Inc. (U.S.), and others.

The encephalomalacia market CAGR would be 6.1% during the forecast period.

The Americas would lead the encephalomalacia market.

Asia Pacific would enjoy the fastest growth in the encephalomalacia market.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Encephalomalacia Market, by Type

6.1 Introduction

6.2 Leukoencephalomalacia

6.2.1 Market Estimates & Forecast, 2017-2023

6.3 Polioencephalomalacia

6.3.1 Market Estimates & Forecast, 2017-2023

7. Global Encephalomalacia Market, by Diagnosis

7.1 Introduction

7.2 Blood tests

7.2.1 Market Estimates & Forecast, 2017-2023

7.3 Brain Scans

7.3.1 Market Estimates & Forecast, 2017-2023

7.4 Others

7.4.1 Market Estimates & Forecast, 2017-2023

8. Global Encephalomalacia Market, by Treatment

8.1 Introduction

8.2 Medical Treatment

8.2.1 Market Estimates & Forecast, 2017-2023

8.3 Surgery

8.3.1 Market Estimates & Forecast, 2017-2023

9. Global Encephalomalacia Market, by End User

9.1 Introduction

9.2 Hospitals & clinics

9.2.1 Market Estimates & Forecast, 2017-2023

9.3 Research laboratories

9.3.1 Market Estimates & Forecast, 2017-2023

9.4 Others

9.4.1 Market Estimates & Forecast, 2017-2023

10. Global Encephalomalacia Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 U.K

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12. Company Profiles

12.1 Fujifilm Holdings

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 GE Healthcare

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Siemens Healthcare

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Philips Healthcare

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Shimadzu Corporation

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Toshiba Medical Systems Corporation

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Carestream Health

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others


13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical Industry

14 Appendix
LIST OF TABLES

Table 1 Encephalomalacia Industry Synopsis, 2017-2023

Table 2 Global Encephalomalacia Market Estimates and Forecast, 2017-2023, (USD Million)

Table 3 Global Encephalomalacia Market by Region, 2017-2023, (USD Million)

Table 4 Global Encephalomalacia Market by Types, 2017-2023, (USD Million)

Table 5 Global Encephalomalacia Market by Diagnosis, 2017-2023, (USD Million)

Table 6 Global Encephalomalacia Market by Treatment, 2017-2023, (USD Million)

Table 7 Global Encephalomalacia Market by End Users, 2017-2023, (USD Million)

Table 8 North America Encephalomalacia Market by Types, 2017-2023, (USD Million)

Table 9 North America Encephalomalacia Market by Diagnosis, 2017-2023, (USD Million)

Table 10 North America Encephalomalacia Market by Treatment, 2017-2023, (USD Million)

Table 11 North America Encephalomalacia Market by End Users, 2017-2023, (USD Million)

Table 12 US Encephalomalacia Market by Types, 2017-2023, (USD Million)

Table 13 US Encephalomalacia Market by Diagnosis, 2017-2023, (USD Million)

Table 14 US Encephalomalacia Market by Treatment, 2017-2023, (USD Million)

Table 15 US Encephalomalacia Market by End Users, 2017-2023, (USD Million)

Table 16 Canada Encephalomalacia Market by Types, 2017-2023, (USD Million)

Table 17 Canada Encephalomalacia Market by Diagnosis, 2017-2023, (USD Million)

Table 18 Canada Encephalomalacia Market by Treatment, 2017-2023, (USD Million)

Table 19 Canada Encephalomalacia Market by End Users, 2017-2023, (USD Million)

Table 20 South America Encephalomalacia Market by Types, 2017-2023, (USD Million)

Table 21 South America Encephalomalacia Market by Diagnosis, 2017-2023, (USD Million)

Table 22 South America Encephalomalacia Market by Treatment, 2017-2023, (USD Million)

Table 23 South America Encephalomalacia Market by End Users, 2017-2023, (USD Million)

Table 24 Europe Encephalomalacia Market by Types, 2017-2023, (USD Million)

Table 25 Europe Encephalomalacia Market by Diagnosis, 2017-2023, (USD Million)

Table 26 Europe Encephalomalacia Market by Treatment, 2017-2023, (USD Million)

Table 27 Europe Encephalomalacia Market by End Users, 2017-2023, (USD Million)

Table 28 Western Europe Encephalomalacia Market by Types, 2017-2023, (USD Million)

Table 29 Western Europe Encephalomalacia Market by Diagnosis, 2017-2023, (USD Million)

Table 30 Western Europe Encephalomalacia Market by Treatment, 2017-2023, (USD Million)

Table 31 Western Europe Encephalomalacia Market by End Users, 2017-2023, (USD Million)

Table 32 Eastern Europe Encephalomalacia Market by Types, 2017-2023, (USD Million)

Table 33 Eastern Europe Encephalomalacia Market by Diagnosis, 2017-2023, (USD Million)

Table 34 Eastern Europe Encephalomalacia Market by Treatment, 2017-2023, (USD Million)

Table 35 Eastern Europe Encephalomalacia Market by End Users, 2017-2023, (USD Million)

Table 36 Asia Pacific Encephalomalacia Market by Types, 2017-2023, (USD Million)

Table 37 Asia Pacific Encephalomalacia Market by Diagnosis, 2017-2023, (USD Million)

Table 38 Asia Pacific Encephalomalacia Market by Treatment, 2017-2023, (USD Million)

Table 39 Asia Pacific Encephalomalacia Market by End Users, 2017-2023, (USD Million)

Table 40 Middle East & Africa Encephalomalacia Market by Types, 2017-2023, (USD Million)

Table 41 Middle East & Africa Encephalomalacia Market by Diagnosis, 2017-2023, (USD Million)

Table 42 Middle East & Africa Encephalomalacia Market by Treatment, 2017-2023, (USD Million)

Table 43 Middle East & Africa Encephalomalacia Market by End Users, 2017-2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Encephalomalacia Market

Figure 3 Segmentation Market Dynamics for Encephalomalacia Market

Figure 4 Global Encephalomalacia Market Share, by Diagnosis 2016

Figure 5 Global Encephalomalacia Market Share, by Treatment 2016

Figure 6 Global Encephalomalacia Market Share, by End Users, 2016

Figure 7 Global Encephalomalacia Market Share, by Region, 2016

Figure 8 North America Encephalomalacia Market Share, by Country, 2016

Figure 9 Europe Encephalomalacia Market Share, by Country, 2016

Figure 10 Asia Pacific Encephalomalacia Market Share, by Country, 2016

Figure 11 Middle East & Africa Encephalomalacia Market Share, by Country, 2016

Figure 12 Global Encephalomalacia Market: Company Share Analysis, 2016 (%)

Figure 13 Fujifilm Holdings: Key Financials

Figure 14 Fujifilm Holdings: Segmental Revenue

Figure 15 Fujifilm Holdings: Geographical Revenue

Figure 16 GE Healthcare: Key Financials

Figure 17 GE Healthcare: Segmental Revenue

Figure 18 GE Healthcare: Geographical Revenue

Figure 19 Siemens Healthcare: Key Financials

Figure 20 Siemens Healthcare: Segmental Revenue

Figure 21 Siemens Healthcare: Geographical Revenue

Figure 22 Philips Healthcare: Key Financials

Figure 23 Philips Healthcare: Segmental Revenue

Figure 24 Philips Healthcare: Geographical Revenue

Figure 25 Shimadzu Corporation.: Key Financials

Figure 26 Shimadzu Corporation: Segmental Revenue

Figure 27 Shimadzu Corporation: Geographical Revenue

Figure 28 Toshiba Medical Systems Corporation: Key Financials

Figure 29 Toshiba Medical Systems Corporation: Segmental Revenue

Figure 30 Toshiba Medical Systems Corporation: Geographical Revenue

Figure 31 Carestream Health.: Key Financials

Figure 32 Carestream Health: Segmental Revenue

Figure 33 Carestream Health: Geographical Revenue